

**OROSTAT 8%- epinephrine hydrochloride solution**  
**Gingi-Pak a Division of the Belport**

*Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, [click here](#).*

-----

**Orostat Solution**

**Active Ingredient**

**Active ingredient**

8% DL-Epinephrine-HCl w/w.

**Purpose**

**Purpose**  
. Hemostyptic

**Description**

**DESCRIPTION** Orostat® is designed for use as a retraction agent or a topically applied vasoconstrictor used to control capillary bleeding and oral tissue seepage, giving fast, positive action and leaving a clean, debris-free field.

**Inactive Ingredient**

purified water, sodium hydrosulfite, sodium thiosulfate, sodium monophosphate, sodium chloride, EDTA, methylparaben, propylparaben, benzyl alcohol

**Keep out of reach if children**

**Keep out of reach of children.**

**Storage**

Store in a cool dark place. Avoid excessive heat above 40C (104F). A brown color change indicates onset of oxidation with reduced potency.

**Uses**

**Uses** For the control of bleeding or topical hemostasis in routine dental procedures including: implantation, root canals, gingivectomy, frenectomy, tissue retraction, oral surgery, and crown and bridge preparations.

**Do not use**

Do not use in individuals with cardiovascular disease, diabetes, hyperthyroidism, hypertension, arteriosclerosis or treated with tricyclic antidepressants. Systemic reactions are intensified by inhalation of anesthetics containing halogen or cyclopentane.

**Warnings**

**Warnings** For topical applications only.

**Directions**

Orostat should be used at room temperature with cotton pellets, sponge or syringe with tips. Orostat can be soaked into unmedicated retraction cord or braid which is then packed into the gingival sulcus. Remove the cord after several minutes and rinse or flush well before taking the impression. The area along with the preparation should be thoroughly dried for silicone and rubber-based impression materials. The area and the preparation should be rinsed and very wet for impressions. If persistent bleeding should occur, apply Orostat with pressure to the exposed capillaries using cotton tipped applicators. Scrubbing or bumishing is of questionable value and could be injurious to gingival tissue and is not recommended.

**Principal Display-Orostat 8%**

**OROSTAT**® Rx only ◀ OPEN HERE

NDC 10129-006-02

**8%**

**DL-Epinephrine-HCl Topical Hemostatic Solution**

REF 10145


**15cc**

**Contains:** DL Epinephrine HCl 8% in an aqueous vehicle with buffering agents.

EN - DL Epinephrine HCl Solution  
DE - DL Epinephrin HCl Lösung  
FR - Solution HCl épinéphrine DL  
NL - DL epinefrine HCl Solution  
IT - Soluzione DL Epinefrina HCl  
ES - Solución La epinefrina HCl DL  
PT - Solução DL epinefrina HCl  
SV - DL Epinefrin HCl lösning  
DA - DL Adrenalin HCl opløsning  
FI - DL Adrenaliini HCl Solution  
EL - Λύση DL επινεφρίνη HCl

**Caution:** Federal law restricts this product to sale or use on the order of a dentist. Avoid excessive heat above 40 °C (104 °F).

**GINGI-PAK**  
Manufactured by: Gingi-Pak  
4825 Calle Alto  
Camarillo, CA 93011 USA  
www.gingi-pak.com



# OROSTAT 8%

epinephrine hydrochloride solution

## Product Information

Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC:10 129-006
Route of Administration	SUBGINGIVAL, PERIODONTAL, DENTAL		

## Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
EPINEPHRINE HYDROCHLORIDE (UNII: WBB0470O38) (EPINEPHRINE - UNII:YKH834O4BH)	EPINEPHRINE HYDROCHLORIDE	1200 mg in 15 mL

## Inactive Ingredients

Ingredient Name	Strength
SODIUM DITHIONITE (UNII: 2K5B8F6ES1)	37.5 mg in 15 mL
SODIUM THIO SULFATE (UNII: HX1032V43M)	15 mg in 15 mL
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS (UNII: KH7I04HPUU)	37.5 mg in 15 mL
SODIUM CHLORIDE (UNII: 451W47IQ8X)	49.5 mg in 15 mL
PROPYLPARABEN (UNII: Z8IX2SC1OH)	4.95 mg in 15 mL
BENZYL ALCOHOL (UNII: LKG8494WBH)	0.15 mL in 15 mL
EDETIC ACID (UNII: 9G34HU7RV0)	1.995 mg in 15 mL
METHYLPARABEN (UNII: A2I8C7HI9T)	10.05 mg in 15 mL

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:10 129-006-02	15 mL in 1 BOTTLE, GLASS; Type 0: Not a Combination Product	04/04/1990	

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		04/04/1990	

**Labeler** - Gingi-Pak a Division of the Belport (008480121)

**Registrant** - Jeff Nichols (008480121)

## Establishment

Name	Address	ID/FEI	Business Operations
Gingi-Pak a Division of the Belport		008480121	manufacture(10 129-006)

